Volcano's CEO sees $2B market for heart stent Dx; Analogic forks over $83M for Canadian ultrasound maker;

 @FierceMedDev: Samsung med device sales spike in 2012. Item | Follow @FierceMedDev

@MarkHFierce: Abbott is beginning a bioresorbable stent trial in the U.S. Big news for the company and its stent rivals alike. More | Follow @MarkHFierce

 @DamianFierce: $LIFE is teaming up with Boston Children's Hospital to develop genomics-based diagnostics. News | Follow @DamianFierce

> Volcano CEO Scott Huennekens ($VOLC) said during the J.P. Morgan Healthcare Conference in San Francisco that the company's diagnostic to spot patients who need heart stents could lead to a $2 billion market over the next 10 years. Story

> Analogic ($ALOG) will buy Canadian ultrasound system maker Ultrasonix Medical for $83 million. Story

> Jerusalem device company Brainsway has seen its stock soar, following FDA approval for its device to address depression when drug treatments fail to work, Bloomberg reports. Story

> Amedica, a spine and orthopedic implant and devicemaker, obtained a $231.5 million senior secured credit facility from GE Capital. The new funding will support the Maryland company's expansion. Item

> Riverain Technologies won FDA 510(k) clearance for new software designed to make conventional chest X-rays clearer and help radiologists rapidly confirm placement of tubes, lines and wires. Release

> Canada's Sernova is pursuing a diabetes treatment that combines an implanted device with a cell therapy. Story

Biotech News

 @FierceBiotech: Buyout buzz: Biopharma players staying focused on bolt-on deals. Report | Follow @FierceBiotech

@JohnCFierce: Medicines Co. spikes after anti-clotting drug impresses in second run at PhIII. Story | Follow @JohnCFierce

> Baxter preps BLA on successful end to PhIII hemophilia drug study. More

> Payer risk outrivals regulatory jitters as biggest biotech hurdle. News

Pharma News

@FiercePharma: Will Bausch + Lomb choose IPO over a sale to pharma? Related Q: Can Warburg Pincus get its $10B+ asking price? More | Follow @FiercePharma

@EricPFierce: COO Perez says Cubist well positioned in new hospital-centric payer world. "The world has turned and we are Cinderella now." | Follow @EricPFierce

 @AlisonBFierce: Altravax landed $1.2M from NIAID to advance its dengue vaccine and hepatitis therapeutic. More | Follow @AlisonBFierce

> AbbVie CFO sees no need for big acquisition. Report

> Swiss insurer jumps into legal fight over Bayer's Yasmin. News

> Teva CEO says job cuts are small part of efficiency plans. Story

Drug Delivery News

> Alnylam prepares for U.K. Phase I and plans for the future. Article

> Agile snags $15M loan to push pipeline products forward. News

> FDA approves EMD Serono-Pfizer's Rebif auto-injector. Item

> FDA grants orphan label to eye cancer chemo-delivery combo. Story

Biomarkers News

> Biomarkers could tag chemo heart risk. Item

> Stem cell factor could improve ovarian cancer prognosis. Article

> Crescendo Bioscience deploys $28M Series D to market RA Dx biomarker test. News

> New target could improve treatment of deadly pancreatic cancer. Story

 

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,